LENSAR (LNSR) to Release Quarterly Earnings on Thursday

LENSAR (NASDAQ:LNSR) is expected to post its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect LENSAR to post earnings of ($0.10) per share and revenue of $20.30 million for the quarter. Individuals can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Friday, March 6, 2026 at 8:30 AM ET.

LENSAR Price Performance

NASDAQ LNSR opened at $11.69 on Tuesday. LENSAR has a 52 week low of $8.96 and a 52 week high of $17.31. The firm has a 50 day moving average of $12.00 and a two-hundred day moving average of $11.85. The stock has a market capitalization of $139.58 million, a PE ratio of -2.66 and a beta of 0.69.

Institutional Investors Weigh In On LENSAR

Large investors have recently modified their holdings of the company. Royal Bank of Canada increased its holdings in shares of LENSAR by 212.4% in the 4th quarter. Royal Bank of Canada now owns 11,277 shares of the company’s stock valued at $131,000 after acquiring an additional 7,667 shares during the period. Barclays PLC boosted its stake in LENSAR by 10.3% during the 4th quarter. Barclays PLC now owns 14,857 shares of the company’s stock worth $173,000 after purchasing an additional 1,389 shares during the period. State Street Corp grew its position in LENSAR by 4.6% during the 4th quarter. State Street Corp now owns 123,720 shares of the company’s stock worth $1,439,000 after purchasing an additional 5,470 shares during the last quarter. Dynamic Technology Lab Private Ltd grew its position in LENSAR by 436.6% during the 4th quarter. Dynamic Technology Lab Private Ltd now owns 54,166 shares of the company’s stock worth $630,000 after purchasing an additional 44,072 shares during the last quarter. Finally, Wells Fargo & Company MN increased its stake in LENSAR by 69.4% in the fourth quarter. Wells Fargo & Company MN now owns 10,734 shares of the company’s stock valued at $125,000 after purchasing an additional 4,398 shares during the period. 40.15% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

LNSR has been the subject of several recent analyst reports. Wall Street Zen upgraded LENSAR to a “hold” rating in a research note on Friday, November 28th. Weiss Ratings reissued a “sell (d-)” rating on shares of LENSAR in a report on Thursday, January 22nd. Two analysts have rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Reduce” and a consensus target price of $15.00.

About LENSAR

LENSAR, Inc, headquartered in Orlando, Florida, is a medical technology company specializing in advanced laser systems for ophthalmic surgery. Its flagship product, the LENSAR Laser System, combines proprietary three-dimensional imaging with precision-guided femtosecond laser delivery to perform critical steps in cataract procedures, including capsulotomy creation, lens fragmentation and corneal incisions.

Founded in 2005, LENSAR has concentrated its research and development efforts on enhancing surgical accuracy and patient outcomes in cataract treatment.